These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31682300)

  • 61. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
    Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
    FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation.
    Kjøller L; Kanse SM; Kirkegaard T; Rodenburg KW; Rønne E; Goodman SL; Preissner KT; Ossowski L; Andreasen PA
    Exp Cell Res; 1997 May; 232(2):420-9. PubMed ID: 9168821
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Recombinant plasminogen activator inhibitor type 1: a review of structural, functional, and biological aspects.
    Reilly TM; Mousa SA; Seetharam R; Racanelli AL
    Blood Coagul Fibrinolysis; 1994 Feb; 5(1):73-81. PubMed ID: 8180342
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Purification and characterization of active and latent forms of recombinant plasminogen activator inhibitor 1 produced in Escherichia coli.
    Seetharam R; Dwivedi AM; Duke JL; Hayman AC; Walton HL; Huckins NR; Kamerkar SM; Corman JI; Woodeshick RW; Wilk RR
    Biochemistry; 1992 Oct; 31(41):9877-82. PubMed ID: 1382596
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation.
    Nar H; Bauer M; Stassen JM; Lang D; Gils A; Declerck PJ
    J Mol Biol; 2000 Mar; 297(3):683-95. PubMed ID: 10731421
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis.
    Leik CE; Su EJ; Nambi P; Crandall DL; Lawrence DA
    J Thromb Haemost; 2006 Dec; 4(12):2710-5. PubMed ID: 17010152
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Analysis of a two-domain binding site for the urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex in low-density-lipoprotein-receptor-related protein.
    Andersen OM; Petersen HH; Jacobsen C; Moestrup SK; Etzerodt M; Andreasen PA; Thøgersen HC
    Biochem J; 2001 Jul; 357(Pt 1):289-96. PubMed ID: 11415462
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator.
    Horn IR; van den Berg BM; Moestrup SK; Pannekoek H; van Zonneveld AJ
    Thromb Haemost; 1998 Nov; 80(5):822-8. PubMed ID: 9843178
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Synthetic peptides derived from the sequence around the plasmin cleavage site in vitronectin. Use in mapping the PAI-1 binding site.
    Gechtman Z; Sharma R; Kreizman T; Fridkin M; Shaltiel S
    FEBS Lett; 1993 Jan; 315(3):293-7. PubMed ID: 7678553
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Structural and functional characterization of vitronectin-derived RGD-containing peptides from human hemofiltrate.
    Ständker L; Enger A; Schulz-Knappe P; Wohn KD; Germer M; Raida M; Forssmann WG; Preissner KT
    Eur J Biochem; 1996 Oct; 241(2):557-63. PubMed ID: 8917456
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The composition of complexes between plasminogen activator inhibitor 1, vitronectin and either thrombin or tissue-type plasminogen activator.
    van Meijer M; Stoop A; Smilde A; Preissner KT; van Zonneveld AJ; Pannekoek H
    Thromb Haemost; 1997 Mar; 77(3):516-21. PubMed ID: 9066004
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Distal hinge of plasminogen activator inhibitor-1 involves its latency transition and specificities toward serine proteases.
    Wang Q; Shaltiel S
    BMC Biochem; 2003 Jul; 4():5. PubMed ID: 12848892
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Redirection of the reaction between activated protein C and a serpin to the substrate pathway.
    Komissarov AA; Andreasen PA; Declerck PJ; Kamikubo Y; Zhou A; Gruber A
    Thromb Res; 2008; 122(3):397-404. PubMed ID: 18045665
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Identification of the plasminogen activator inhibitor-1 binding heptapeptide in vitronectin.
    Mimuro J; Muramatsu S; Kurano Y; Uchida Y; Ikadai H; Watanabe S; Sakata Y
    Biochemistry; 1993 Mar; 32(9):2314-20. PubMed ID: 7680229
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Orientation of heparin-binding sites in native vitronectin. Analyses of ligand binding to the primary glycosaminoglycan-binding site indicate that putative secondary sites are not functional.
    Gibson AD; Lamerdin JA; Zhuang P; Baburaj K; Serpersu EH; Peterson CB
    J Biol Chem; 1999 Mar; 274(10):6432-42. PubMed ID: 10037735
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin.
    Stefansson S; Lawrence DA
    Nature; 1996 Oct; 383(6599):441-3. PubMed ID: 8837777
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Functional interaction of plasminogen activator inhibitor type 1 (PAI-1) and heparin.
    Ehrlich HJ; Keijer J; Preissner KT; Gebbink RK; Pannekoek H
    Biochemistry; 1991 Jan; 30(4):1021-8. PubMed ID: 1703436
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Vitronectin and substitution of a beta-strand 5A lysine residue potentiate activity-neutralization of PA inhibitor-1 by monoclonal antibodies against alpha-helix F.
    Schousboe SL; Egelund R; Kirkegaard T; Preissner KT; Rodenburg KW; Andreasen PA
    Thromb Haemost; 2000 May; 83(5):742-51. PubMed ID: 10823273
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A peptide accelerating the conversion of plasminogen activator inhibitor-1 to an inactive latent state.
    Mathiasen L; Dupont DM; Christensen A; Blouse GE; Jensen JK; Gils A; Declerck PJ; Wind T; Andreasen PA
    Mol Pharmacol; 2008 Sep; 74(3):641-53. PubMed ID: 18559377
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Mutational analysis of plasminogen activator inhibitor-1.
    Wind T; Jensen JK; Dupont DM; Kulig P; Andreasen PA
    Eur J Biochem; 2003 Apr; 270(8):1680-8. PubMed ID: 12694181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.